Simmons Bank Buys 2,317 Shares of Bristol Myers Squibb Company $BMY

Simmons Bank grew its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 5.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 45,309 shares of the biopharmaceutical company’s stock after buying an additional 2,317 shares during the quarter. Simmons Bank’s holdings in Bristol Myers Squibb were worth $2,097,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Brighton Jones LLC grew its holdings in shares of Bristol Myers Squibb by 33.4% in the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Flossbach Von Storch SE bought a new position in shares of Bristol Myers Squibb in the first quarter worth approximately $699,000. Greenleaf Trust grew its holdings in Bristol Myers Squibb by 3.3% in the 1st quarter. Greenleaf Trust now owns 31,179 shares of the biopharmaceutical company’s stock worth $1,902,000 after acquiring an additional 1,002 shares during the last quarter. Linden Thomas Advisory Services LLC grew its holdings in Bristol Myers Squibb by 2.4% in the 1st quarter. Linden Thomas Advisory Services LLC now owns 26,742 shares of the biopharmaceutical company’s stock worth $1,631,000 after acquiring an additional 639 shares during the last quarter. Finally, First National Bank & Trust Co. of Newtown grew its holdings in Bristol Myers Squibb by 3.5% in the 1st quarter. First National Bank & Trust Co. of Newtown now owns 27,541 shares of the biopharmaceutical company’s stock worth $1,680,000 after acquiring an additional 940 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Stock Performance

Bristol Myers Squibb stock opened at $46.50 on Thursday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $63.33. The stock has a market cap of $94.66 billion, a price-to-earnings ratio of 18.75, a PEG ratio of 2.23 and a beta of 0.33. The stock’s 50 day simple moving average is $45.26 and its two-hundred day simple moving average is $46.73.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.52 by $0.11. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. During the same period in the previous year, the company posted $1.80 earnings per share. The firm’s revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd were issued a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 5.3%. The ex-dividend date was Friday, October 3rd. Bristol Myers Squibb’s payout ratio is 83.78%.

Insider Buying and Selling

In related news, EVP David V. Elkins sold 56,000 shares of the business’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president owned 167,379 shares of the company’s stock, valued at $7,922,048.07. The trade was a 25.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.07% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

BMY has been the topic of several recent analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a research note on Tuesday, October 14th. Dbs Bank raised Bristol Myers Squibb to a “moderate buy” rating in a research note on Thursday, October 2nd. Morgan Stanley reiterated a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Citigroup reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research report on Monday, October 13th. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $57.23.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.